


INFORMATION DISCLOSURE STATEMENT	<i>Complete if known</i>	
	Application Number: 10/714,699	
	Filing Date: November 17, 2003	
	First Named Inventor: Cunningham et al.	
	Group Art Unit: Not yet assigned 1649	
Examiner Name: Not yet assigned Hayes		
Our File No. 1801-PO3049US1		



SHEET 1 OF 2

UNITED STATES PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
RH	A1	6,262,024	July 17, 2001	Cunningham et al.

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
no copies	B1	WO 02/11026	WO	07-09-1992	Rao et al.
	B2	WO 03/06116	WO	04-01-1993	Lin et al.

OTHER PRIOR ART - NON-PATENT DOCUMENTS		
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
RH	C1	Mihelich et al., Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A ₂ inhibitors, SPI, Biochimica et Biophysica Acta 1441 (1999), pages 223-228.
	C2	Springer, D, An Update on Inhibitors of Human 14kDa Type II s-PLA ₂ in Development, Current Pharmaceutical Design (2001), Vol. 7, pages 181-198.
	C3	Abraham et al., Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIa secretory phospholipase A ₂ , in patients with suspected sepsis and organ failure, Critical Care Medicine, (2003) Vol. 31, No. 3, pages 718-728.
	C4	Eagleson, et al., Rescue of Both Rapidly and Slowly Degenerating Neurons in the Dorsal Lateral Geniculate Nucleus of Adult Rats by a Cortically Derived Neuron Survival Factor, Experimental Neurology, (1992) Vol. 116, pages 156-162.
	C5	Eagleson et al., Different Populations of Dorsal Lateral Geniculate Nucleus Neurons Have Concentration-Specific Requirements for a Cortically Derived Neuron Survival Factor, Experimental Neurology, (1990), Vol. 110: pages 284-290.

EXAMINER'S SIGNATURE	/Robert Hayes/	DATE CONSIDERED	03/05/2007
----------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

Complete if known

Application Number: 10/714,699

Filing Date: November 17, 2003

First Named Inventor: Cunningham et al.

Group Art Unit: ~~Not yet assigned~~ 1649

Examiner Name: ~~Not yet assigned~~

Our File No. 1801-PO3049US1

SHEET 2 OF 2



RE	C6	Paterson et al., α -Cardiac Actin is the Major Sarcomeric Isoform Expressed in Embryonic Avian Skeletal Muscle, Science (1984), Vol. 224, pages 1436-1438.
↓	C7	Cunningham et al., Identification of a Survival-Promoting Peptide in Medium Conditioned by Oxidatively Stressed Cell Lines of Nervous System Origin, The Journal of Neuroscience (1998), Vol. 18, No. 18., pages 7047-7060.
↓	C8	Cunningham et al., Identification of the Human cDNA for New Survival/Evasion Peptide (DSEP): Studies <i>in Vitro</i> and <i>in Vivo</i> of Overexpression by Neural Cells, Experimental Neurology (2002), Vol. 177, pages 32-39.
↓	C9	Cunningham et al., Calreticulin Binding and Other Biological Activities of Survival Peptide Y-P30 Including Effects of Systemic Treatment of Rats, Experimental Neurology (2000), Vol. 163, pages 457-468.

EXAMINER'S
SIGNATURE

/Robert Hayes/

DATE
CONSIDERED

03/05/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.